Reported 10 months ago
Pharmigene announced on June 20, 2024, its acquisition of Emergent BioSolutions' aseptic drug plant in Kon-Town, Maryland, for $30 million USD (approximately NT$960 million). This move enhances Pharmigene's global Contract Development and Manufacturing Organization (CDMO) capabilities and signifies its strong presence in the U.S. The acquired plant spans 86,900 square feet with 4 aseptic drug production lines supporting various processes. Pharmigene plans to expand its market globally beyond the U.S., leveraging the plant's production capacity and regulatory certifications. The acquisition is expected to boost Pharmigene's revenue and solidify its position as a leader in the biopharmaceutical industry.
Source: YAHOO